AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi

AstraZeneca has fired another shot in its bladder cancer competition with Merck's Keytruda, with the FDA clearing its PD-L1 inhibitor Imfinzi, used alongside standard of care, to become the first immunotherapy combination regimen for patients with high-risk non-muscle-invasive bladder cancer.